Business Update
InSite Vision meets with the U.S. FDA on pre-NDA discussions for AzaSite
Published in Medical Letter on the CDC and FDA, May 31st, 2006
The purpose of the meeting was to discuss the proposed new drug application (NDA) submission for AzaSite, the company's ocular anti-infective product. InSite recently announced the successful completion of the second of two required phase III clinical trials to evaluate the safety and efficacy of AzaSite. In this study, patients treated with AzaSite had a significantly higher clinical resolution rate, the trial's primary efficacy end point, and a significantly higher...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Breast Cancer
Women's experiences during mammography affect adherence to rescreening - Chickenpox Vaccine
Ethnic disparities have been eliminated for varicella vaccination in U.S. children - Diet & Nutrition
U.S. FDA perspectives on health claims for food labels are presented - Mental Health
Newer antidepressants were not associated with suicide risk - Virology
Risk factors for West Nile virus disease are described - Acid Reflux
U.S. FDA approves AstraZeneca's NEXIUM in youth 12-17 for short-term treatment of GERD - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
